Company environment · Targeted small molecules · FDA CDER & EMA
Biomarker-selected oncology NDA, sNDA & EU Type II variation
Original NDA, supplemental sNDA, and EMA Type II variation gates.
1What does this company do?
Oncology sponsor developing a targeted kinase inhibitor gated by a molecular companion diagnostic.
2Where is the product on its way to patients?
Biomarker-selected oral oncology therapy across original NDA, supplemental sNDA, and EMA Type II variation filings.
- 1Discovery & Lead Selection
- 2IND-Enabling Nonclinical
- 3Clinical Development (IND / CTA)
- 4Registration & Dossier Review
- The product is here
- 5Approval & Launch Readiness
- 6Commercial Lifecycle & GMP
3What is happening right now?
The filing governance committee convenes tomorrow, and working clinical, labeling, and CDx records conflict.
4Tasks
5 tasks in the 81-task Biopharma Bench V0.2 suite, graded against expert rubric criteria.
Sealed partner records & open showcases
This environment is reconstructed from a confidential drug or device program, so its records, tasks, and rubrics remain sealed.
To inspect complete workspaces, candidate deliverables, trajectories, and rubric criteria end to end, open the two public companion showcases:
Havenor Therapeutics (synthetic sterile-injectables CMC/MSAT) →
Broad Institute (public FDA CDER IND 167326 record) →